Irritable bowel syndrome (IBS) is a common diagnosis given to people with chronic, otherwise unexplained abdominal pain, irregular bowel movements, and a host of other possible symptoms [1 Trusted SourcePubMedGo to source]. Some people with IBS have diarrhea as a prominent feature and belong to an IBS subcategory called IBS-diarrhea, or IBS-D for short.
Although no cure currently exists for IBS-D, mounting evidence shows that lifestyle approaches may improve the condition and your quality of life. Such approaches may include eating a non-inflammatory diet, taking supplements to support digestion, reducing stress, correcting gut microbial imbalances, and making sure the bowels move regularly.
What Is IBS-D?
IBS-D is a subtype of IBS, which is a functional gastrointestinal disorder, or FGID [1 Trusted SourcePubMedGo to source]. In FGIDs, the digestive tract stops doing its job properly, but not because of any structural issues or biochemical irregularities that can be detected in x-rays, blood tests, or microscopic views of the intestine . The Rome Foundation, which supplies doctors with a list of criteria to help them diagnose IBS, characterizes FGIDs as gut-brain axis disorders with the following :
Disturbed motility (muscular activity of the intestines)
Hypersensitive GI tract nerves
Abnormal functioning of the gut lining or immune system
Imbalances in gut microbiota
Impaired central nervous system communication
Estimates suggest that 10% to 12% of people in the United States have IBS, andfemales are three times as likely as males to have an IBS diagnosis [1 Trusted SourcePubMedGo to source].
About one-third of IBS sufferers have IBS-D, which means at least 25% of bowel movements appear as loose stools that are mushy without clear edges or completely liquid [1 Trusted SourcePubMedGo to source]. Another third of IBS sufferers have IBS with constipation — IBS-C — indicated when 25% of bowel movements have hard or sausage-shaped stools that are lumpy. A final third of IBS patients have IBS-M, or mixed IBS, in which at least 25% of bowel movements reflect diarrhea or constipation [1 Trusted SourcePubMedGo to source].
Symptoms of IBS-D
Typically, IBS-D symptoms include sporadic abdominal pain or cramping and chronic diarrhea. IBS-D sufferers may also experience any of the following [1 Trusted SourcePubMedGo to source]:
Abdominal bloating after meals or with stress
Feeling more full than makes sense
Dyspepsia or indigestion: burning sensations in the upper abdomen, often along with bloating, belching, and nausea
Mood disorders: emotions or moods that are inconsistent with the current situation and disrupt normal daily functioning and relationships
Chronic migraines: having headaches on at least 15 days per month with migraines on at least eight of those days for at least three months in a row
Interstitial cystitis: inflammation of the bladder that causes bladder or pelvic pressure and pain
Fibromyalgia: widespread muscle or joint pain, often with fatigue and disruptions in sleep, memory, and mood
Rarely, the sensation of incomplete or insufficient bowel movements; constipation may occur periodically in IBS-D
What Causes IBS-D?
Although the exact cause of IBS-D is unclear, research points to these possible underlying factors:
Gut inflammation(gastroenteritis): a higher concentration of inflammatory cells, such as mast cells, cytokines, and eosinophils, may affect the nervous system and impair gut function [1 Trusted SourcePubMedGo to source, 10].
Malabsorption of bile acids: if bile acid from the gallbladder is not properly absorbed in the upper small intestine, it may flow into the large intestine and cause diarrhea-predominant IBS [1 Trusted SourcePubMedGo to source]; nearly 25% of IBS-D patients may have bile acid diarrhea of unknown cause [15 Trusted SourcePubMedGo to source].
People with IBS-D may be more likely to have a disorder called exocrine pancreatic insufficiency (EPI), in which the enzymes the pancreas produces to digest food are too few or otherwise unable to help with normal digestion. One study found that roughly 6% of people with IBS-D had EPI [16 Trusted SourcePubMedGo to source]. At this point, the jury is out on whether EPI can be considered a cause of IBS or vice-versa, but it’s worth asking your doctor about it just to be sure.
How To Treat IBS-D
The optimal treatment plan for IBS-D consists of these steps:
Eat a healthier diet.
If IBS-D symptoms persist, eat a low-FODMAP diet.
Correct microbial imbalances.
Normalize (slow down) gut motility.
1. Eat a Healthier Diet
Frequently, just by making simple changes to the diet, people have seen significant improvements in their IBS-D symptoms . First-line dietary changes include reducing your intake of sugar, processed foods, alcohol, and caffeine, and increasing the amount of fruits and vegetables in your diet.
2. Eat a Low-FODMAP Diet
If the first-line dietary changes don’t seem to improve your IBS-D symptoms after a couple of weeks, the next thing to try is a low-FODMAP diet. The acronym FODMAP stands for fermentable oligosaccharides, disaccharides, monosaccharides, and polyols that occur in specific foods. These sugars and starches can feed gut dysbiosis, making high-FODMAP foods hard for IBS patients to digest and irritating to the gut lining. Clinical trials have found that a low-FODMAP diet improved GI symptoms and stool consistency and frequency, as well as the quality of life, anxiety, and work productivity, in people with IBS-D [18 Trusted SourcePubMedGo to source, 19 Trusted SourcePubMedGo to source, 20 Trusted SourcePubMedGo to source].
3. Support Digestion
If you’re still not seeing improvements to your IBS-D symptoms, certain supplements may give your gut the boost it needs. Probiotics, immunoglobulins, and digestive enzymes may give your digestive system a hand at breaking down food and absorbing nutrients.
If EPI appears to be an issue, pancreatic enzyme replacement therapy (called PERT for short), a doctor-prescribed treatment for EPI, may be helpful [16 Trusted SourcePubMedGo to source].
4. Reduce Stress
Stress is a pretty regular part of most people’s lives and a likely contributor to your IBS-D symptoms. Several types of evidence-based practices have shown positive effects at reducing stress and specifically improving life for IBS patients.
Psychological support. In people with moderate to severe IBS-D, working with therapists who offered cognitive-behavioral therapy (CBT) or mindfulness-based stress reduction (MBSR), helped improve their quality of life [2 Trusted SourcePubMedGo to source].
If the previous approaches don’t seem to help, SIBO or other types of dysbiosis may be part of the picture. Probiotic therapy is my first choice for treating dysbiosis, but for those who don’t respond to probiotics, herbal antimicrobials or prescription antibiotics may be warranted.
Diarrhea happens when gut motility is too fast. Diarrhea causes dehydration and malabsorption, both of which can become serious issues if diarrhea becomes chronic. If IBS-related diarrhea persists after consistently applying dietary changes, digestive supports, stress reduction practices, and microbial balancing, the following conventional medications may be helpful.
Loperamide. Brand name Imodium, this over-the-counter anti-diarrheal may help slow motility temporarily, but few clinical trials have researched its use in IBS [42 Trusted SourcePubMedGo to source].
Peppermint oil is an herbal supplement that may relax the smooth muscles in the digestive tract, helping to decrease pain, bloating, and bowel movement urgency. But it commonly produces side effects, including heartburn or indigestion [42 Trusted SourcePubMedGo to source], so test it carefully.
If your doctor finds your stool has high levels of steatocrit, bile acid malabsorption (BAM) is likely causing your chronic diarrhea. Conventional medications that can help address this include bile acid binders [42 Trusted SourcePubMedGo to source], such as:
Important Notes About Medication:
The FDA considers drugs as a bottom-of-the-list option for IBS, to be considered only if lifestyle changes don’t help .
Dicyclomine: With the brand name Bentyl, this is another prescription drug that has been used to treat pain in IBS-D, but the FDA does not recommend using it because of side effects, including fatigue, dizziness, dry eyes, and dry mouth [42 Trusted SourcePubMedGo to source].
How Is IBS-D Diagnosed?
I recommend working with a gut specialist to find out whether you have IBS-D. As is true for all IBS subtypes, doctors have no clear path to diagnosing IBS-D. Without specific blood tests or other diagnostic panels to indicate IBS-D, primary care doctors and gastroenterologists typically have to first rule out conditions caused by structural or biochemical problems, including [44 Trusted SourcePubMedGo to source]:
Inflammatory bowel disease (IBD)
Chronic GI infections
Primary bile acid diarrhea
If general blood tests, various breath tests, or colonoscopies don’t indicate these conditions, doctors may then use a set of questions, called the Rome IV criteria, combined with your health and family histories to decide whether you likely suffer from IBS-D [45 Trusted SourcePubMedGo to source].
Final Thoughts on IBS-D
IBS-D is simply a subtype of IBS that has diarrhea as a prominent symptom. It’s possible to switch back and forth between IBS-D and IBS-C, putting you in the mixed-type — or IBS-M — a category of people who suffer from IBS. In any case, the label is not as important as your symptoms and how they affect your life.
The good news is that when the right supports are in place, people can and do shift to a symptom-free existence and a higher quality of life. Until then, when IBS-D is part of your day-to-day life, this article can be your guide to finding appropriate care and giving your body the special support it needs.
Kurin M, Cooper G. Irritable bowel syndrome with diarrhea: Treatment is a work in progress. Cleve Clin J Med. 2020 Jul 31;87(8):501-511. doi: 10.3949/ccjm.87a.19011. PMID: 32737051. Trusted SourcePubMedGo to source
Cassar GE, Youssef GJ, Knowles S, Moulding R, Austin DW. Health-Related Quality of Life in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Gastroenterol Nurs. 2020 May/Jun;43(3):E102-E122. doi: 10.1097/SGA.0000000000000530. PMID: 32487960. Trusted SourcePubMedGo to source
Chen B, Kim JJ, Zhang Y, Du L, Dai N. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol. 2018 Jul;53(7):807-818. doi: 10.1007/s00535-018-1476-9. Epub 2018 May 14. PMID: 29761234. Trusted SourcePubMedGo to source
Schmulson M, Bielsa MV, Carmona-Sánchez R, Hernández A, López-Colombo A, López Vidal Y, Peláez-Luna M, Remes-Troche JM, Tamayo JL, Valdovinos MA. Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: an evidence-based review. Rev Gastroenterol Mex. 2014 Apr-Jun;79(2):96-134. English, Spanish. doi: 10.1016/j.rgmx.2014.01.004. Epub 2014 May 23. PMID: 24857420. Trusted SourcePubMedGo to source
Takakura W, Pimentel M. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome – An Update. Front Psychiatry. 2020 Jul 10;11:664. doi: 10.3389/fpsyt.2020.00664. PMID: 32754068; PMCID: PMC7366247. Trusted SourcePubMedGo to source
Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002 Dec;47(12):2639-43. doi: 10.1023/a:1021039032413. PMID: 12498278. Trusted SourcePubMedGo to source
Liu HN, Wu H, Chen YZ, Chen YJ, Shen XZ, Liu TT. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis. Dig Liver Dis. 2017 Apr;49(4):331-337. doi: 10.1016/j.dld.2017.01.142. Epub 2017 Jan 21. PMID: 28179092. Trusted SourcePubMedGo to source
Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterol. 2009 Aug 7;15(29):3591-6. doi: 10.3748/wjg.15.3591. PMID: 19653335; PMCID: PMC2721231.
Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. J Gastroenterol Hepatol. 2010 Feb;25(2):252-8. doi: 10.1111/j.1440-1746.2009.06149.x. PMID: 20136989. Trusted SourcePubMedGo to source
Catassi C, Alaedini A, Bojarski C, Bonaz B, Bouma G, Carroccio A, Castillejo G, De Magistris L, Dieterich W, Di Liberto D, Elli L, Fasano A, Hadjivassiliou M, Kurien M, Lionetti E, Mulder CJ, Rostami K, Sapone A, Scherf K, Schuppan D, Trott N, Volta U, Zevallos V, Zopf Y, Sanders DS. The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update. Nutrients. 2017 Nov 21;9(11):1268. doi: 10.3390/nu9111268. PMID: 29160841; PMCID: PMC5707740. Trusted SourcePubMedGo to source
Deng Y, Misselwitz B, Dai N, Fox M. Lactose Intolerance in Adults: Biological Mechanism and Dietary Management. Nutrients. 2015 Sep 18;7(9):8020-35. doi: 10.3390/nu7095380. PMID: 26393648; PMCID: PMC4586575. Trusted SourcePubMedGo to source
Atkinson W, Sheldon TA, Shaath N, et al
Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial
Aziz I, Mumtaz S, Bholah H, Chowdhury FU, Sanders DS, Ford AC. High Prevalence of Idiopathic Bile Acid Diarrhea Among Patients With Diarrhea-Predominant Irritable Bowel Syndrome Based on Rome III Criteria. Clin Gastroenterol Hepatol. 2015 Sep;13(9):1650-5.e2. doi: 10.1016/j.cgh.2015.03.002. Epub 2015 Mar 10. PMID: 25769413. Trusted SourcePubMedGo to source
Leeds JS, Hopper AD, Sidhu R, Simmonette A, Azadbakht N, Hoggard N, Morley S, Sanders DS. Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency. Clin Gastroenterol Hepatol. 2010 May;8(5):433-8. doi: 10.1016/j.cgh.2009.09.032. Epub 2009 Oct 14. PMID: 19835990. Trusted SourcePubMedGo to source
McKenzie, Y.A., Bowyer, R.K., Leach, H., Gulia, P., Horobin, J., O’Sullivan, N.A., Pettitt, C., Reeves, L.B., Seamark, L., Williams, M., Thompson, J. & Lomer, M.C.E. (2016) British Dietetic Association systematic review and evidence‐based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 29, 549– 575 doi:10.1111/jhn.12385
Zahedi MJ, Behrouz V, Azimi M. Low fermentable oligo-di-mono-saccharides and polyols diet versus general dietary advice in patients with diarrhea-predominant irritable bowel syndrome: A randomized controlled trial. J Gastroenterol Hepatol. 2018 Jun;33(6):1192-1199. doi: 10.1111/jgh.14051. Epub 2018 Feb 21. PMID: 29159993. Trusted SourcePubMedGo to source
Eswaran SL, Chey WD, Han-Markey T, Ball S, Jackson K. A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D. Am J Gastroenterol. 2016 Dec;111(12):1824-1832. doi: 10.1038/ajg.2016.434. Epub 2016 Oct 11. PMID: 27725652. Trusted SourcePubMedGo to source
Eswaran S, Chey WD, Jackson K, Pillai S, Chey SW, Han-Markey T. A Diet Low in Fermentable Oligo-, Di-, and Monosaccharides and Polyols Improves Quality of Life and Reduces Activity Impairment in Patients With Irritable Bowel Syndrome and Diarrhea. Clin Gastroenterol Hepatol. 2017 Dec;15(12):1890-1899.e3. doi: 10.1016/j.cgh.2017.06.044. Epub 2017 Jun 28. PMID: 28668539. Trusted SourcePubMedGo to source
Hod K, Sperber AD, Ron Y, Boaz M, Dickman R, Berliner S, Halpern Z, Maharshak N, Dekel R. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. Neurogastroenterol Motil. 2017 Jul;29(7). doi: 10.1111/nmo.13037. Epub 2017 Mar 8. PMID: 28271623. Trusted SourcePubMedGo to source
Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol. 2018 May 25;18(1):71. doi: 10.1186/s12876-018-0788-9. PMID: 29801486; PMCID: PMC5970461. Trusted SourcePubMedGo to source
Sun YY, Li M, Li YY, Li LX, Zhai WZ, Wang P, Yang XX, Gu X, Song LJ, Li Z, Zuo XL, Li YQ. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Sci Rep. 2018 Feb 14;8(1):2964. doi: 10.1038/s41598-018-21241-z. PMID: 29445178; PMCID: PMC5813237. Trusted SourcePubMedGo to source
Preston K, Krumian R, Hattner J, de Montigny D, Stewart M, Gaddam S. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. Benef Microbes. 2018 Sep 18;9(5):697-706. doi: 10.3920/BM2017.0105. Epub 2018 Jun 11. PMID: 29888656. Trusted SourcePubMedGo to source
Rogha M, Esfahani MZ, Zargarzadeh AH. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol Hepatol Bed Bench. 2014 Summer;7(3):156-63. PMID: 25120896; PMCID: PMC4129566. Trusted SourcePubMedGo to source
Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F, Pande A, Majeed S, Karri SK. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J. 2016 Feb 27;15:21. doi: 10.1186/s12937-016-0140-6. PMID: 26922379; PMCID: PMC4769834. Trusted SourcePubMedGo to source
Wilson D, Evans M, Weaver E, Shaw AL, Klein GL. Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome. Clin Med Insights Gastroenterol. 2013 Dec 5;6:49-60. doi: 10.4137/CGast.S13200. PMID: 24833942; PMCID: PMC4020402. Trusted SourcePubMedGo to source
Zhou C, Zhao E, Li Y, Jia Y, Li F. Exercise therapy of patients with irritable bowel syndrome: A systematic review of randomized controlled trials. Neurogastroenterol Motil. 2019 Feb;31(2):e13461. doi: 10.1111/nmo.13461. Epub 2018 Sep 19. PMID: 30232834. Trusted SourcePubMedGo to source
Miller V, Carruthers HR, Morris J, Hasan SS, Archbold S, Whorwell PJ. Hypnotherapy for irritable bowel syndrome: an audit of one thousand adult patients. Aliment Pharmacol Ther. 2015 May;41(9):844-55. doi: 10.1111/apt.13145. Epub 2015 Mar 4. PMID: 25736234. Trusted SourcePubMedGo to source
Hasan SS, Pearson JS, Morris J, Whorwell PJ. SKYPE HYPNOTHERAPY FOR IRRITABLE BOWEL SYNDROME: Effectiveness and Comparison with Face-to-Face Treatment. Int J Clin Exp Hypn. 2019 Jan-Mar;67(1):69-80. doi: 10.1080/00207144.2019.1553766. PMID: 30702396; PMCID: PMC6538308. Trusted SourcePubMedGo to source
Zhong C, Qu C, Wang B, Liang S, Zeng B. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence. J Clin Gastroenterol. 2017 Apr;51(4):300-311. doi: 10.1097/MCG.0000000000000814. PMID: 28267052. Trusted SourcePubMedGo to source
García-Collinot G, Madrigal-Santillán EO, Martínez-Bencomo MA, Carranza-Muleiro RA, Jara LJ, Vera-Lastra O, Montes-Cortes DH, Medina G, Cruz-Domínguez MP. Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis. Dig Dis Sci. 2020 Apr;65(4):1134-1143. doi: 10.1007/s10620-019-05830-0. Epub 2019 Sep 23. PMID: 31549334. Trusted SourcePubMedGo to source
Greco A, Caviglia GP, Brignolo P, Ribaldone DG, Reggiani S, Sguazzini C, Smedile A, Pellicano R, Resegotti A, Astegiano M, Bresso F. Glucose breath test and Crohn’s disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response. Scand J Gastroenterol. 2015;50(11):1376-81. doi: 10.3109/00365521.2015.1050691. Epub 2015 May 19. PMID: 25990116. Trusted SourcePubMedGo to source
Wang F, Feng J, Chen P, Liu X, Ma M, Zhou R, Chang Y, Liu J, Li J, Zhao Q. Probiotics in Helicobacter pylori eradication therapy: Systematic review and network meta-analysis. Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):466-475. doi: 10.1016/j.clinre.2017.04.004. Epub 2017 May 25. PMID: 28552432. Trusted SourcePubMedGo to source
Besirbellioglu BA, Ulcay A, Can M, Erdem H, Tanyuksel M, Avci IY, Araz E, Pahsa A. Saccharomyces boulardii and infection due to Giardia lamblia. Scand J Infect Dis. 2006;38(6-7):479-81. doi: 10.1080/00365540600561769. PMID: 16798698. Trusted SourcePubMedGo to source
Demirel G, Celik IH, Erdeve O, Saygan S, Dilmen U, Canpolat FE. Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants. Eur J Pediatr. 2013 Oct;172(10):1321-6. doi: 10.1007/s00431-013-2041-4. Epub 2013 May 24. PMID: 23703468. Trusted SourcePubMedGo to source
Dinleyici EC, Eren M, Dogan N, Reyhanioglu S, Yargic ZA, Vandenplas Y. Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection. Parasitol Res. 2011 Mar;108(3):541-5. doi: 10.1007/s00436-010-2095-4. Epub 2010 Oct 5. PMID: 20922415. Trusted SourcePubMedGo to source
Chen C, Tao C, Liu Z, Lu M, Pan Q, Zheng L, Li Q, Song Z, Fichna J. A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. Phytother Res. 2015 Nov;29(11):1822-7. doi: 10.1002/ptr.5475. Epub 2015 Sep 24. PMID: 26400188. Trusted SourcePubMedGo to source
Chedid V, Dhalla S, Clarke JO, Roland BC, Dunbar KB, Koh J, Justino E, Tomakin E, Mullin GE. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014 May;3(3):16-24. doi: 10.7453/gahmj.2014.019. PMID: 24891990; PMCID: PMC4030608. Trusted SourcePubMedGo to source
Di Pierro F, Bertuccioli A, Giuberti R, Saponara M, Ivaldi L. Role of a berberine-based nutritional supplement in reducing diarrhea in subjects with functional gastrointestinal disorders. Minerva Gastroenterol Dietol. 2020 Mar;66(1):29-34. doi: 10.23736/S1121-421X.19.02649-7. PMID: 32283882. Trusted SourcePubMedGo to source
Brenner DM, Sayuk GS. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea. Adv Ther. 2020 Jan;37(1):83-96. doi: 10.1007/s12325-019-01116-z. Epub 2019 Nov 9. PMID: 31707713. Trusted SourcePubMedGo to source
Munjal A, Dedania B, Cash BD. Current and emerging pharmacological approaches for treating diarrhea-predominant irritable bowel syndrome. Expert Opin Pharmacother. 2020 Jan;21(1):63-71. doi: 10.1080/14656566.2019.1691524. Epub 2019 Nov 18. PMID: 31738621. Trusted SourcePubMedGo to source
Aziz I, Simrén M. The overlap between irritable bowel syndrome and organic gastrointestinal diseases. Lancet Gastroenterol Hepatol. 2020 Nov 12:S2468-1253(20)30212-0. doi: 10.1016/S2468-1253(20)30212-0. Epub ahead of print. PMID: 33189181. Trusted SourcePubMedGo to source
I care about answering your questions and sharing my knowledge with you. Leave a comment or connect with me on social media asking any health question you may have and I just might incorporate it into our next listener questions podcast episode just for you!
Transform your health
Every product is science-based, validated by real-world use, and personally vetted by Dr. Ruscio, DNM, DC.